TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25991385

Group type: EXPERIMENTAL
Intervention: Lateral wedge insoles
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Barefoot walking
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Mobility shoe
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control shoe
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Typical wedge
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Supported wedge
Number of subjects: 70
Study: 23777311

Group type: EXPERIMENTAL
Intervention: Paliperidone extended-release (ER)
Number of subjects: 184
Study: 21832305

Group type: EXPERIMENTAL
Intervention: CHO+CAFF (Carbohydrate + Caffeine)
Number of subjects: 6

Group type: COMPARATOR
Intervention: CHO (Carbohydrate)
Number of subjects: 6

Group type: COMPARATOR
Intervention: WAT (Water)
Number of subjects: 6
Study: 19637480

Group type: EXPERIMENTAL
Intervention: Silicone rubber impression
Number of subjects: 389

Group type: COMPARATOR
Intervention: Agar/alginate combination impression
Number of subjects: 389
Study: 16946030

Group type: EXPERIMENTAL
Intervention: 30 min exercise at 70% peak oxygen consumption
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 60 min exercise at 70% peak oxygen consumption
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 120 min exercise at 70% peak oxygen consumption
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Men
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Exercise duration
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Sex
Number of subjects: 15
Study: 14691688

Group type: EXPERIMENTAL
Intervention: desferrioxamine
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: deferiprone (L1)
Number of subjects: 22

Group type: COMPARATOR
Intervention: baseline
Number of subjects: 22

Group type: COMPARATOR
Intervention: 1 year follow up
Number of subjects: 22

Group type: COMPARATOR
Intervention: 3 year follow up
Number of subjects: 22
Study: 11531864

Group type: EXPERIMENTAL
Intervention: Totally extraperitoneal (TEP) repair
Number of subjects: 200

Group type: COMPARATOR
Intervention: Shouldice repair
Number of subjects: 200
Study: 9037444

Group type: EXPERIMENTAL
Intervention: Omeprazole (40 mg once daily) alone (group A) for 4 weeks
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Omeprazole (40 mg once daily) + tripotassium dicitrato bismuthate (TDB; 240 mg bid) for 4 weeks (group B)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Omeprazole (20 mg bid) for 2 weeks + amoxicillin (1 g bid only 2nd week) (group A)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Tripotassium dicitrato bismuthate (TDB) monotherapy for 4 weeks (group B)
Number of subjects: 52
Study: 8100221

Group type: EXPERIMENTAL
Intervention: Single oral (10 mg) and i.m. (0.5 mg) medication
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Multiple oral dosing (5 mg on trial days 1, 2, 3, 5, 7, 9, 11 and 13)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Multiple oral dosing (5 mg on trial days 5 to 14) with initial i.m. loading doses (0.5 mg i.m. on trial days 1, 2 and 4)
Number of subjects: 24

Group type: COMPARATOR
Intervention: i.m. administration
Number of subjects: 24
Study: 3729461

Group type: EXPERIMENTAL
Intervention: IHC (angiotensin-induced hypertension chemotherapy)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Non-IHC (control)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: IHC
Number of subjects: 40

Group type: COMPARATOR
Intervention: Non-IHC
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Open trial (IHC)
Number of subjects: 40
Study: 29743284

Group type: EXPERIMENTAL
Intervention: Vertebroplasty
Number of subjects: 180

Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 180

Group type: COMPARATOR
Intervention: Both groups (Vertebroplasty and Sham)
Number of subjects: 180
Study: 26961287

Group type: EXPERIMENTAL
Intervention: Porous hydroxyapatite/collagen composite (HAp/Col)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Porous β‐tricalcium phosphate (β‐TCP)
Number of subjects: 126
Study: 25028994

Group type: EXPERIMENTAL
Intervention: Aerobic Interval Training (AIT)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Nonlinear Resistance Training (NRT)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 33
Study: 22037965

Group type: EXPERIMENTAL
Intervention: Couple-skills intervention (Side by Side)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Couples Control Program (cancer education)
Number of subjects: 72
Study: 20569841

Group type: EXPERIMENTAL
Intervention: Janani Suraksha Yojana (JSY) payments
Number of subjects: 0
Study: 17906015

Group type: EXPERIMENTAL
Intervention: Advised-coitus group
Number of subjects: 210

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 210
Study: 16336070

Group type: EXPERIMENTAL
Intervention: Phone + Mail Counseling condition
Number of subjects: 72

Group type: COMPARATOR
Intervention: Mail Support condition
Number of subjects: 72
Study: 12084138

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)
Number of subjects: 187

Group type: COMPARATOR
Intervention: Control
Number of subjects: 187
Study: 7797925

Group type: EXPERIMENTAL
Intervention: Trivalent cold-adapted recombinant (CR) influenza virus vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Monovalent A/H1N1, A/H3N2, or B vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 2159706

Group type: EXPERIMENTAL
Intervention: Weekly intermittent regimen of AZT and 2',3'-dideoxycytidine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Weekly alternating regimen of AZT and 2',3'-dideoxycytidine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Monthly alternating regimen of AZT and 2',3'-dideoxycytidine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Zidovudine (AZT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 2',3'-dideoxycytidine
Number of subjects: 0
Study: 6986104

Group type: EXPERIMENTAL
Intervention: Early extubation
Number of subjects: 38

Group type: COMPARATOR
Intervention: Late extubation
Number of subjects: 38
Study: 31597624

Group type: EXPERIMENTAL
Intervention: Early controlled motion (ECM) of the ankle, performed five times a day from week 3 to week 8 after rupture.
Number of subjects: 130

Group type: COMPARATOR
Intervention: Immobilisation for 8 weeks.
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Early controlled motion (ECM) of the ankle.
Number of subjects: 130
Study: 30277627

Group type: EXPERIMENTAL
Intervention: Intravaginal ulinastatin (UTI) administration
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study: 27690682

Group type: EXPERIMENTAL
Intervention: Nitroglycerin (6 puffs, 2.4 mg sublingual) and glucagon (1 mg intravenously)
Number of subjects: 455

Group type: COMPARATOR
Intervention: Sterile water (6 puffs) and hyoscine-n-butyl bromide (20 mg intravenously)
Number of subjects: 455
Study: 25427566

Group type: EXPERIMENTAL
Intervention: CPP‐ACP‐containing cream (GC Tooth Mouse, non‐fluoride) after fluoride toothpaste (1,400 ppm NaF)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Prolonged application of fluoride toothpaste (1,400 ppm NaF; positive control)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Prolonged application of fluoride-free toothpaste (negative control)
Number of subjects: 13
Study: 23617551

Group type: EXPERIMENTAL
Intervention: Budesonide 400 μg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Formoterol 12 μg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Budesonide 400 μg + Formoterol 12 μg
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 22084331

Group type: EXPERIMENTAL
Intervention: Dosing assessment every 12 weeks (n = 124)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Dosing assessment every 4 weeks (n = 126)
Number of subjects: 250
Study: 19408012

Group type: EXPERIMENTAL
Intervention: Hepatectomy with adjuvant TACE (HT arm)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Hepatectomy alone (HA arm)
Number of subjects: 115
Study: 17218576

Group type: EXPERIMENTAL
Intervention: Dexamethasone (0.5 mg/kg; maximum, 10 mg)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Saline solution (placebo)
Number of subjects: 69
Study: 16398842

Group type: EXPERIMENTAL
Intervention: Bisphosphonate therapy (n = 5)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Calcium and vitamin D supplementation (control group)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Calcium and vitamin D supplementation combined with bisphosphonate treatment (non-trial patients, n = 11)
Number of subjects: 12
Study: 12875343

Group type: EXPERIMENTAL
Intervention: Locally implanted gentamicin (miniseptopal or sponge)
Number of subjects: 20
Study: 10582505

Group type: EXPERIMENTAL
Intervention: Rubber surgical gloves (thicknesses: 0.24, 0.61, and 1.02 mm)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Cotton glove
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Rubber glove
Number of subjects: 10

Group type: COMPARATOR
Intervention: Barehanded
Number of subjects: 10
Study: 8542565

Group type: EXPERIMENTAL
Intervention: Group education and written notification of excessive prescribing
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Written notification of excessive prescribing only
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 54
Study: 1878641

Group type: EXPERIMENTAL
Intervention: Budesonide 800 micrograms
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Budesonide 400 micrograms
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 7143158

Group type: EXPERIMENTAL
Intervention: Hypnosis
Number of subjects: 49

Group type: COMPARATOR
Intervention: Nonhypnotic techniques
Number of subjects: 49
Study: 31511398

Group type: EXPERIMENTAL
Intervention: PCSK9 loss-of-function variants (LOFV)
Number of subjects: 10
Study: 28115488

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Chlorthalidone
Number of subjects: 228
Study: 25425257

Group type: EXPERIMENTAL
Intervention: Locomotion Replacement Training (LRT)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Standing (STA)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 10

Group type: COMPARATOR
Intervention: All conditions (CON, STA, LRT)
Number of subjects: 10
Study: 24829493

Group type: EXPERIMENTAL
Intervention: CanolaDHA (high-oleic acid canola oil with docosahexaenoic acid)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Canola (conventional canola oil)
Number of subjects: 130

Group type: COMPARATOR
Intervention: CornSaff (blend of corn and safflower oil)
Number of subjects: 130

Group type: COMPARATOR
Intervention: FlaxSaff (blend of flax and safflower oils)
Number of subjects: 130

Group type: COMPARATOR
Intervention: CanolaOleic (high-oleic acid canola oil)
Number of subjects: 130
Study: 23033885

Group type: EXPERIMENTAL
Intervention: Electronic diary (e-diary) with integrated peak flow meter
Number of subjects: 47

Group type: COMPARATOR
Intervention: Paper diary
Number of subjects: 47
Study: 19744315

Group type: EXPERIMENTAL
Intervention: Group physiotherapy sessions
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Recommendations from women attending group sessions
Number of subjects: 22
Study: 17123710

Group type: EXPERIMENTAL
Intervention: Transmeatal cochlear laser (TCL) stimulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo stimulation
Number of subjects: 0
Study: 14989693

Group type: EXPERIMENTAL
Intervention: SMCP alone
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Hynes alone
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: SMCP+Hynes
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: SMCP repair
Number of subjects: 42
Study: 12472324

Group type: EXPERIMENTAL
Intervention: rHuEPO (40,000 units administered weekly by subcutaneous injection)
Number of subjects: 1302

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1302

Group type: EXPERIMENTAL
Intervention: rHuEPO
Number of subjects: 1302
Study: 9795455

Group type: COMPARATOR
Intervention: alpha E beta 7 integrin expression on T cells of lamina propria (LPL)
Number of subjects: 38

Group type: COMPARATOR
Intervention: alpha E beta 7 integrin expression on intra-epithelial lymphocytes (IEL)
Number of subjects: 38

Group type: COMPARATOR
Intervention: CD4/CD8 ratio in LPL
Number of subjects: 38

Group type: COMPARATOR
Intervention: Regional differences in CD4/CD8 ratio
Number of subjects: 38

Group type: COMPARATOR
Intervention: alpha E beta 7 integrin expression in LPL
Number of subjects: 38
Study: 7635134

Group type: EXPERIMENTAL
Intervention: German version of Broadbent's Cognitive Failures Questionnaire
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inventories of trait anxiety, coping styles, and action control
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Maximum likelihood factor analysis of the questionnaire
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Unidimensionality of the construct
Number of subjects: 0
Study: 2236459

Group type: EXPERIMENTAL
Intervention: Enciprazine (5 mg t.i.d., 10 mg t.i.d., and 20 mg t.i.d.)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Enciprazine
Number of subjects: 0
Study: 389282

Group type: EXPERIMENTAL
Intervention: Betamethasone phosphate 0.1%
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clobetasone butyrate 0.1%
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30535378

Group type: EXPERIMENTAL
Intervention: Education and cognitive ability
Number of subjects: 0
Study: 27837660

Group type: EXPERIMENTAL
Intervention: Psychoeducation + active CBM-I
Number of subjects: 0

Group type: COMPARATOR
Intervention: Psychoeducation + control CBM-I
Number of subjects: 0
Study: 25078875

Group type: EXPERIMENTAL
Intervention: Educational intervention based on Su Corazón, Su Vida curriculum, consisting of 8 educational sessions.
Number of subjects: 90
Study: 23972025

Group type: EXPERIMENTAL
Intervention: Tamoxifen (MA.12 trial)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo (MA.12 trial)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Tamoxifen (BC cohort)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: N/A (BC cohort)
Number of subjects: 101
Study: 21164503

Group type: EXPERIMENTAL
Intervention: 5-day high-fat high-calorie (HFHC) dietary intervention
Number of subjects: 46
Study: 19757196

Group type: EXPERIMENTAL
Intervention: LMWH (Nadroparin)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 16889458

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral group therapy (CBGT) for 12 weeks
Number of subjects: 56

Group type: COMPARATOR
Intervention: Sertraline 100 mg/day for 12 weeks
Number of subjects: 56
Study: 15171752

Group type: EXPERIMENTAL
Intervention: Troglitazone followed by rosiglitazone (4 mg/day) or pioglitazone (30 mg/day)
Number of subjects: 172

Group type: COMPARATOR
Intervention: Control group (no antidiabetic medication)
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Troglitazone followed by rosiglitazone or pioglitazone
Number of subjects: 172
Study: 11566518

Group type: EXPERIMENTAL
Intervention: Topical anesthesia (oxybuprocaine 0.4%)
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: Combined anesthesia (topical anesthesia and propofol sedation)
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: Retrobulbar/peribulbar anesthesia (prilocaine 1.5%)
Number of subjects: 291
Study: 9054252

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine infusion (50 ng.kg-1.min-1 for 30 min before induction, then 7 ng.kg-1.min-1 until end of surgery)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine infusion
Number of subjects: 80

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 80
Study: 8201140

Group type: EXPERIMENTAL
Intervention: Alcohol (BAC 0.10%)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 3608513

Group type: EXPERIMENTAL
Intervention: Homologous human fibronectin (300 micrograms/ml), mixed with gentamicin and artificial tears, 4 times a day
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control (gentamicin and artificial tears)
Number of subjects: 6
Study: 29370352

Group type: EXPERIMENTAL
Intervention: Tissue liquefaction liposuction (TLL)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Suction-assisted liposuction (SAL)
Number of subjects: 31
Study: 27309589

Group type: EXPERIMENTAL
Intervention: Instructor-led debriefing (high-level facilitation)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Within-team debriefing (low-level facilitation)
Number of subjects: 37
Study: 25658097

Group type: EXPERIMENTAL
Intervention: EFV/FTC/TDF
Number of subjects: 157

Group type: COMPARATOR
Intervention: ABC/3TC+EFV
Number of subjects: 157
Study: 24021497

Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (20-50 mg/d)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate
Number of subjects: 129
Study: 21917907

Group type: EXPERIMENTAL
Intervention: Leptin administration (twice daily injections)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo administration (twice daily injections)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Weight loss maintenance
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Leptin administration
Number of subjects: 0
Study: 17557312

Group type: EXPERIMENTAL
Intervention: Doxapram (respiratory stimulant), dosage and duration not specified
Number of subjects: 0
Study: 17007369

Group type: EXPERIMENTAL
Intervention: Mizolastine (10 mg once daily for 3 weeks)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Cetirizine (10 mg once daily for 3 weeks)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 12781882

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiation and surgery
Number of subjects: 1116

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiation and surgery (concurrent)
Number of subjects: 1116

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiation and surgery (sequential)
Number of subjects: 1116
Study: 12413260

Group type: EXPERIMENTAL
Intervention: Technique P (IVECG signal from NaHCO3 flushed catheter)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Technique G (IVECG signal from guide wire)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Technique G
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Technique P
Number of subjects: 100
Study: 9669144

Group type: EXPERIMENTAL
Intervention: Calcium supplementation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined therapy with calcium and vitamin D
Number of subjects: 0
Study: 7928312

Group type: EXPERIMENTAL
Intervention: Migraineurs
Number of subjects: 845
Study: 2691780

Group type: EXPERIMENTAL
Intervention: Cinitapride
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Metoclopramide
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (healthy individuals)
Number of subjects: 16
Study: 4835842

Group type: EXPERIMENTAL
Intervention: (87m)Sr scintigraphy
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: (99m)Tc polyphosphate scintigraphy
Number of subjects: 201

Group type: COMPARATOR
Intervention: x-ray
Number of subjects: 201

Group type: COMPARATOR
Intervention: x-ray and (87m)Sr surveys
Number of subjects: 201
Study: 31831363

Group type: EXPERIMENTAL
Intervention: DHA-rich fish oil (2400 mg/d) for 8 weeks
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo for 8 weeks
Number of subjects: 50
Study: 31593702

Group type: EXPERIMENTAL
Intervention: Dupilumab (300 mg weekly subcutaneous injections)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Dupilumab
Number of subjects: 47
Study: 28165552

Group type: EXPERIMENTAL
Intervention: VLCKD1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: VLCKD2
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: VLCKD3
Number of subjects: 0

Group type: COMPARATOR
Intervention: VLCKD
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control Groups (CG1 and CG2)
Number of subjects: 0
Study: 26030518

Group type: EXPERIMENTAL
Intervention: palbociclib and fulvestrant
Number of subjects: 521

Group type: COMPARATOR
Intervention: placebo and fulvestrant
Number of subjects: 521
Study: 23488834

Group type: EXPERIMENTAL
Intervention: Mild propofol sedation
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Deep propofol sedation
Number of subjects: 30
Study: 20976617

Group type: EXPERIMENTAL
Intervention: 16-week Theory of Mind (ToM) treatment
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study: 19135798

Group type: EXPERIMENTAL
Intervention: Remifentanil (two different clinically relevant doses)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 17303791

Group type: EXPERIMENTAL
Intervention: Chromium treatment (400 microg of chromium daily in the form of chromium yeast)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 15519185

Group type: EXPERIMENTAL
Intervention: methylprednisolone, 5 mg/kg body weight
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: methylprednisolone, 10 mg/kg body weight
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (no methylprednisolone)
Number of subjects: 36
Study: 11300234

Group type: EXPERIMENTAL
Intervention: Six months of progressive whole‐body resistive training (RT)
Number of subjects: 18
Study: 9021814

Group type: EXPERIMENTAL
Intervention: Identified beta-thalassemia alleles
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Degree of iron overload
Number of subjects: 54
Study: 7931889

Group type: EXPERIMENTAL
Intervention: Intranasal fluticasone propionate, 200 micrograms once daily for 4 weeks
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Intranasal fluticasone propionate, 100 micrograms once daily for 4 weeks
Number of subjects: 249

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Intranasal fluticasone propionate (both dosages)
Number of subjects: 249

Group type: COMPARATOR
Intervention: All groups (including placebo)
Number of subjects: 249
Study: 3076051

Group type: EXPERIMENTAL
Intervention: Sodium fluoride therapy (pure sodium fluoride powder, Ossin, Koreberon)
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Sodium fluoride therapy (Koreberon)
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Sodium fluoride therapy
Number of subjects: 158